[{"id":"e48114c4-2c36-41f9-bc27-1f9242719dc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04284488","created_at":"2021-01-18T20:47:55.803Z","updated_at":"2024-07-02T16:35:32.408Z","phase":"Phase 1/2","brief_title":"Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors","source_id_and_acronym":"NCT04284488","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" EGFR • ROS1","pipe":" | ","alterations":" EGFR wild-type","tags":["EGFR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • dasminapant (APG-1387)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 04/10/2020","start_date":" 04/10/2020","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2023-10-20"},{"id":"33519654-a406-4cd2-9505-88653cfb3f5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00372736","created_at":"2021-01-22T18:52:09.360Z","updated_at":"2024-07-02T16:35:40.958Z","phase":"Phase 1","brief_title":"AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors","source_id_and_acronym":"NCT00372736","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" XIAP","pipe":"","alterations":" ","tags":["XIAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • GEM 640"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 07/27/2006","start_date":" 07/27/2006","primary_txt":" Primary completion: 03/24/2009","primary_completion_date":" 03/24/2009","study_txt":" Completion: 01/06/2012","study_completion_date":" 01/06/2012","last_update_posted":"2023-08-04"},{"id":"a4644e4f-7f77-41bb-aff1-11853d753688","acronym":"","url":"https://clinicaltrials.gov/study/NCT01617668","created_at":"2021-01-18T06:55:54.569Z","updated_at":"2024-07-02T16:37:28.440Z","phase":"Phase 2","brief_title":"A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer","source_id_and_acronym":"NCT01617668","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • LCL161"],"overall_status":"Completed","enrollment":" Enrollment 209","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 09/01/2014","primary_completion_date":" 09/01/2014","study_txt":" Completion: 09/01/2014","study_completion_date":" 09/01/2014","last_update_posted":"2016-10-17"},{"id":"37494a36-42c2-4252-ba85-b6ab705daf26","acronym":"","url":"https://clinicaltrials.gov/study/NCT01188499","created_at":"2021-01-18T04:45:11.810Z","updated_at":"2024-07-02T16:37:31.639Z","phase":"Phase 1b/2a","brief_title":"Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT01188499","lead_sponsor":"TetraLogic Pharmaceuticals","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • irinotecan • birinapant (IGM-9427)"],"overall_status":"Completed","enrollment":" Enrollment 176","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 10/01/2013","primary_completion_date":" 10/01/2013","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2016-05-30"}]